BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis
Status:
Active, not recruiting
Trial end date:
2027-05-18
Target enrollment:
Participant gender:
Summary
To evaluate the long-term safety of BI 655130 (SPESOLIMAB) in patients with moderate to
severely active ulcerative colitis, who have completed treatment in previous trials
To evaluate the long-term efficacy of BI 655130 (SPESOLIMAB) in patients with moderate to
severely active ulcerative colitis, who have completed treatment in previous trials